세계의 뉴로모듈레이션 시장 규모는 2024년에 82억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 188억 달러에 달하며, 2025-2033년의 성장률(CAGR)은 9.2%에 달할 것으로 예측하고 있습니다. 이 시장은 만성질환 및 신경질환의 유병률 증가, 유리한 규제 환경의 도입, 헬스케어 지출의 증가, 디바이스 기술의 현저한 진보, 저침습(MI) 치료에 대한 수요 증가, 연구개발(R&D) 구상에 대한 강력한 투자에 의해 지원되며 견고한 성장을 달성하고 있습니다.
주요 시장 성장 촉진요인 : 신경 변조 시장은 파킨슨병, 만성 통증, 우울증과 같은 만성질환 및 신경질환의 유병률 증가에 의해 주도되고 있습니다. 또한 의료비 지출 증가, 개선된 상환 정책을 제공하는 유리한 규제 시행, 자기공명영상(MRI) 안전 및 충전식 장비 개발 등 신경 변조 장비의 급속한 기술 발전이 시장 성장을 가속하고 있습니다.
주요 시장 동향 : 신경조절 기기에 인공지능(AI) 및 머신러닝(ML) 기술을 통합하여 실시간 모니터링 및 치료 조정을 가능하게 하는 움직임이 있습니다. 또한 현재 진행 중인 연구 및 임상시험의 성공으로 신경조절 치료의 적응증이 확대되고 있으며, 시장도 확대되고 있습니다.
지역적 동향 : 북미는 첨단화된 의료 인프라, 강력한 규제 프레임워크, 높은 의료비 등으로 인해 신경모듈레이션 시장을 주도하고 있습니다. 다른 지역도 의료 인프라 개선, 가처분 소득 증가, 신경조절요법에 대한 인식이 높아지면서 빠르게 성장하고 있습니다.
경쟁 구도 : 뉴로모듈레이션 업계의 주요 시장 참여 기업에는 Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp. 등이 있습니다.
과제와 기회: 주요 과제는 기기 및 시술의 높은 비용으로, 특히 신흥 시장에서 시장 침투를 제한할 수 있다는 점입니다. 또한 기기 이식의 복잡성과 잠재적인 부작용도 걸림돌로 작용하고 있습니다. 그러나 비만이나 중독과 같은 미개발 질환에 대한 잠재적 치료 등 신경모듈레이션의 적용 범위를 확대하는 데에는 비즈니스 기회가 있습니다. 또한 의료비 지출 증가는 그동안 서비스가 제공되지 않았던 영역으로 시장을 확대할 수 있는 큰 기회가 될 것입니다.
만성질환과 신경질환의 유병률 상승
당뇨병, 비만, 심혈관 질환과 같은 만성질환과 파킨슨병, 간질, 우울증과 같은 신경질환의 유병률 증가는 신경모듈레이션 시장의 중요한 촉진요인으로 작용하고 있습니다. 미국 질병예방통제센터(CDC)에 따르면 미국 성인 10명 중 6명이 만성질환을 앓고 있습니다. 또한 10명 중 4명은 2개 이상의 만성질환을 앓고 있습니다. 또한 인도의 노년층 성인의 약 21%가 적어도 한 가지 이상의 만성질환을 앓고 있습니다. 농촌에서는 17%, 도시에서는 29%의 노인이 하나 이상의 만성질환을 앓고 있습니다. 이러한 건강 문제는 합병증을 유발하며, 신경조절요법으로 관리 및 치료할 수 있습니다. 예를 들어 척수자극요법(SCS)은 허리 수술 실패 증후군이나 복합부위통증증후군으로 인한 증상의 통증 완화를 위해 널리 사용되고 있습니다.
의료비 지출 증가
세계 여러 국가에서 헬스케어에 대한 지출 증가, 중산층 인구 증가, 첨단 의료 인프라 구축으로 인해 신경조절요법의 도입이 증가하고 있습니다. 예를 들어 인도의 보건의료에 대한 공공지출은 '23년 GDP의 2.1%, '22년 2.2%에 달할 전망입니다. 또한 인도 정부는 헬스케어 인프라를 강화하기 위해 5만 루피(68억 달러) 상당의 신용 우대 제도를 도입할 계획입니다. 마찬가지로 유럽에서는 2022년 일반 정부 의료비 지출이 1조 2,210억 유로(GDP의 7.7%)에 달할 것으로 예측됩니다. 미국의 의료비 지출은 4.1% 증가하여 4조 5,000억 달러, 1인당 1만 3,493달러에 달할 것으로 예측됩니다. 이러한 확장은 신경조절 산업의 지역 실적을 늘리고 새로운 환자 집단에 이러한 첨단 치료법을 도입하고 있습니다.
유리한 상환 정책 시행
신경조절치료에 대한 지속적인 보상 정책의 개선은 시장 성장을 가속하는 주요 요인으로 작용하고 있습니다. 많은 국가에서 난치성 질환 치료에 신경조절치료의 유용성이 인정됨에 따라 의료 보험 프로바이더들은 일부 신경조절치료를 포함하도록 정책을 개정하고 있습니다. 이러한 변화로 인해 신경 변조 기술은 더 많은 환자들이 이용할 수 있게 되었으며, 2022년에는 미국 인구의 92.1%에 해당하는 3억 4천만 명이 건강 보험에 가입할 것으로 예상됩니다(미국 인구 조사국 조사 결과). 또한 민간의료보험 가입률은 65.6%, 36.1%로 공보험 가입률을 웃돌았습니다. 또한 보험사들은 특히 입원일수 단축과 약물 사용량 감소라는 측면에서 장기적으로 신경모듈레이션의 비용 효율성을 인정하고 있으며, 보험금 상환의 적용 범위가 확대되고 있습니다.
The global neuromodulation market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.8 Billion by 2033, exhibiting a growth rate (CAGR) of 9.2% during 2025-2033. The market is experiencing robust growth, driven by the increasing prevalence of chronic and neurological disorders, imposition of favorable regulatory environment, rising expenditure on healthcare, significant advancements in device technology, and growing demand for minimally invasive (MI) therapies, supported by strong investment in research and development (R&D) initiatives.
Major Market Drivers: The neuromodulation market is driven by the increasing prevalence of chronic diseases and neurological disorders, such as Parkinson's disease, chronic pain, and depression. Moreover, the rising expenditure on healthcare, the implementation of favorable regulations that offer improvements in reimbursement policies, and rapid technological advancements in neuromodulation devices, including the development of magnetic resonance imaging (MRI)-safe and rechargeable devices, are boosting the market growth.
Key Market Trends: There is a trend towards the integration of artificial intelligence (AI) and machine learning (ML) technologies into neuromodulation devices that enable real-time monitoring and adjustments of therapy. Moreover, the expansion of indications for neuromodulation therapies, facilitated by ongoing research and successful clinical trials, is broadening the market expansion.
Geographical Trends: North America dominates the neuromodulation market due to its advanced healthcare infrastructure, robust regulatory framework, and high healthcare expenditure. Other regions are also experiencing rapid growth, driven by improving healthcare infrastructures, increasing disposable incomes, and growing awareness of neuromodulation therapies.
Competitive Landscape: Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., and Nevro Corp., among many others.
Challenges and Opportunities: A major challenge is the high cost of devices and procedures, which can limit market penetration, especially in developing regions. Additionally, the complexity of device implantation and potential side effects pose hurdles. However, opportunities lie in the expanding scope of neuromodulation applications, including potential treatments for untapped medical conditions, such as obesity and addiction. Furthermore, increasing healthcare spending presents a significant opportunity for market expansion into previously underserved areas.
Rising Prevalence of Chronic Diseases and Neurological Disorders
The heightened incidence of chronic diseases such as diabetes, obesity, and cardiovascular conditions, alongside neurological disorders like Parkinson's disease, epilepsy, and depression, is a significant driver for the neuromodulation market. As per the Centre for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. are suffering from chronic diseases. And 4 out of 10 people have more than two chronic conditions. Also, about 21% of the geriatric adults in India have at least one chronic disease. 17% of geriatric people in rural areas and 29% in urban areas suffer from at least one chronic disease. These health issues lead to complications that can be managed or treated through neuromodulation therapies. For instance, spinal cord stimulation (SCS) is widely used for pain relief in conditions that result from failed back surgery syndrome or complex regional pain syndrome.
Increasing Expenditure on Healthcare
Several countries across the globe are witnessing increased adoption of neuromodulation therapies owing to rising expenditure on healthcare, the growing population of the middle class, and the establishment of advanced healthcare infrastructures. For instance, India's public expenditure on healthcare touched 2.1% of GDP in FY23 and 2.2% in FY22. Also, the Indian government is planning to introduce a credit incentive program worth Rs. 50,000 crores (US$ 6.8 billion) to boost the country's healthcare infrastructure. Similarly, in Europe, the general government spending on health amounted to €1221 billion or 7.7% of GDP in 2022. The U.S. healthcare spending saw a hike of 4.1%, reaching $4.5 trillion or $13493/person. This expansion is increasing the geographical footprint of the neuromodulation industry and introducing these advanced therapies to new patient populations.
Implementation of Favorable Reimbursement Policies
The ongoing improvements in reimbursement policies for neuromodulation procedures is a main factor driving the market growth. In many countries, health insurance providers have revised their policies to include several neuromodulation therapies as they recognize their benefits in treating many refractory conditions. These changes have made neuromodulation technologies more accessible to a broader range of patients. In 2022, 92.1 percent of people, or 304.0 million in the U.S., had health insurance at some point during the year, as per the U.S. Census Bureau. Moreover, private health insurance coverage was more prevalent than public coverage, at 65.6 percent and 36.1 percent, respectively. Also, insurers are recognizing the cost-effectiveness of neuromodulation in the long term, especially in terms of reduced hospital stays and medication use, which is expanding the scope of reimbursement coverage.
Internal neuromodulation accounts for the majority of the market share
Based on the neuromodulation market analysis and forecast, internal neuromodulation emerged as the largest segment. It includes advanced therapies, such as spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), among others. They are utilized for treating a wide range of chronic conditions and neurological disorders, including chronic pain, Parkinson's disease, urinary and fecal incontinence, and refractory epilepsy. Moreover, the proven efficacy of internal neuromodulations in improving patient outcomes, significant advancements in device technology that enhance user safety and comfort, and the broadening scope of clinical applications are fueling the neuromodulation market revenue.
Metallic biomaterials hold the largest share of the industry
As per the neuromodulation market report and overview, metallic biomaterials stand out as the largest segment, owing to their critical role in the manufacturing of implants and devices used in neuromodulation therapies, such as electrodes and leads. Metallic biomaterials are favored for their superior electrical conductivity, biocompatibility, and durability. They are essential for ensuring the long-term reliability and performance of neuromodulation devices, particularly those that require chronic implantation or are subject to bodily fluids and tissues. Besides this, the ongoing advancements that improve their functionality and safety, such as coatings to enhance biocompatibility or technologies to reduce the risk of infection, are favoring the neuromodulation market growth.
Parkinson's disease represents the leading market segment
According to the neuromodulation market outlook and trends, Parkinson's disease emerged as the largest segment, reflecting the significant impact and utility of neuromodulation therapies in managing chronic neurological disorders. The increasing utilization of deep brain stimulation (DBS) for the treatment of patients who do not respond adequately to pharmacological treatments is enhancing the market growth. DBS helps in alleviating symptoms such as tremors, rigidity, and bradykinesia, significantly enhancing the quality of life for patients. Moreover, the efficacy of neuromodulation in providing substantial and sustained symptom relief, leading to its widespread adoption in clinical settings, is catalyzing the neuromodulation market share.
North America leads the market, accounting for the largest neuromodulation market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for neuromodulation.
North America accounted for the largest segment in the neuromodulation market, attributed to several key factors, including advanced healthcare infrastructure, strong regulatory support, and substantial investments in research and development (R&D). Moreover, the region is a hub of some of the leading companies in the neuromodulation industry, which drives innovation and market growth through continuous advancements in technology. Additionally, the high prevalence of chronic diseases and neurological disorders, coupled with a well-established healthcare system that facilitates early adoption of new technologies, is contributing to the neuromodulation market revenue.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp., etc.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
The top neuromodulation companies are engaged in enhancing their competitive edge through strategic initiatives, such as mergers, acquisitions, and partnerships. They are investing in research and development (R&D) to innovate and improve their neuromodulation devices. These innovations focus on increasing the precision, effectiveness, and safety of therapies for conditions like chronic pain, Parkinson's disease, and urinary disorders. Additionally, industry leaders are involved in clinical trials to expand the indications for existing technologies, thereby broadening the potential user base. They are also prioritizing obtaining regulatory approvals in new markets to ensure global access to their advanced therapies. Furthermore, major companies are enhancing patient and practitioner engagement through digital platforms that facilitate better monitoring and management of therapy outcomes. This helps them align with the broader trend toward digital health solutions in medical technology, thereby positively impacting the neuromodulation market's recent development and opportunities.
In April 2022, Boston Scientific Corporation (US) received FDA approval for its Vercise Neural Navigator with visualization software, STIMVIEW XT. The device allows medical professionals to view the real-time location of leads, or electrodes, in patients with Parkinson's disease and those undergoing deep brain stimulation (DBS).
In December 2022, Abbott Laboratories received FDA approval for its Eterna spinal cord stimulation (SCS) system. It is a small implantable and rechargeable spinal cord stimulator for treating chronic pain. The neuromodulation device utilizes Abbott's proprietary low-dose BurstDR stimulation.